Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A Randomized, Controlled Trial.

Abstract

Results of a 6 months study with monoclonal anti-TNF alpha antibody in comparison with methotrexate in patients with rheumatoid arthritis. Certolizumab was significantly more efficient than placebo.

Safety profile was comparable to other anti-TNF inhibitors.

Keywords

• Certolizumab Pegol
• Methotrexate
• Active Rheumatoid Arthritis